Some BioPharm News:
StockNewsGazette- December 1st 2017
Northwest Biotherapeutics, Inc. (NWBO) vs. Cytori Therapeutics, Inc. (CYTX): Breaking Down the Biotechnology Industry’s Two Hottest Stocks
Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) shares are up more than 32.16% this year and recently decreased -12.33% or -$0.04 to settle at $0.26. Cytori Therapeutics, Inc. (NASDAQ:CYTX), on the other hand, is down -78.15% year to date as of 11/28/2017. It currently trades at $0.33 and has returned -3.26% during the past week.
Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) and Cytori Therapeutics, Inc. (NASDAQ:CYTX) are the two most active stocks in the Biotechnology industry based on today’s trading volumes. To determine if one is a better investment than the other, we will compare the two companies’ growth, profitability, risk, return, and valuation characteristics, as well as their analyst ratings and sentiment signals.
Cash Flow
The value of a stock is simply the present value of its future free cash flows. NWBO’s free cash flow (“FCF”) per share for the trailing twelve months was -0.02. Comparatively, CYTX’s free cash flow per share was -0.12. On a percent-of-sales basis, NWBO’s free cash flow was -1.02% while CYTX converted -0.09% of its revenues into cash flow. This means that, for a given level of sales, CYTX is able to generate more free cash flow for investors.
Valuation
NWBO trades at a P/S of 125.39, compared to a P/B of 0.92, and a P/S of 1.36 for CYTX. NWBO is the cheaper of the two stocks on book value basis but is expensive in terms of P/E and P/S ratio. Given that earnings are what matter most to investors, analysts tend to place a greater weight on the P/E.
Analyst Price Targets and Opinions
A cheap stock isn’t a good investment if the stock is priced accurately. To get a sense of “value” we must compare the current price to some measure of intrinsic value such as a price target. NWBO is currently priced at a -94.8% to its one-year price target of 5.00. Comparatively, CYTX is -84.13% relative to its price target of 2.08. This suggests that NWBO is the better investment over the next year.
The average investment recommendation on a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell) is 2.00 for NWBO and 2.30 for CYTX, which implies that analysts are more bullish on the outlook for CYTX.
Insider Activity and Investor Sentiment
Analysts often look at short interest, or the percentage of a company’s float currently being shorted by investors, to aid in their outlook for a particular stock. NWBO has a short ratio of 7.38 compared to a short interest of 3.05 for CYTX. This implies that the market is currently less bearish on the outlook for CYTX.
Summary
Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) beats Cytori Therapeutics, Inc. (NASDAQ:CYTX) on a total of 7 of the 14 factors compared between the two stocks. NWBO generates a higher return on investment, has higher cash flow per share and has lower financial risk. NWBO is more undervalued relative to its price target. Finally, CMLS has better sentiment signals based on short interest.
--------------------------------------------
Stock News Journal - Nov 30th 2017 Hesitation to buy this stock might leave you disappointed: MannKind Corporation (MNKD)
MannKind Corporation (NASDAQ:MNKD) market capitalization at present is $366.65M at the rate of $3.16 a share. The firm’s price-to-sales ratio was noted 16.86 in contrast with an overall industry average of 96.51. Most of the active traders and investors are keen to find ways to compare the value of stocks. The price-to-sales ratio offers a simple approach in this case. They just need to take the company’s market capitalization and divide it by the company’s total sales over the past 12 months. The lesser the ratio, the more attractive the investment. During the key period of last 5 years, MannKind Corporation (NASDAQ:MNKD) sales have annually surged 411.30% on average, however its earnings per share growth remained at 17.20%.
How Company Returns Shareholder’s Value?
Dividends is a reward scheme, that a company presents to its shareholders. There can be various forms of dividends, such as cash payment, stocks or any other form. This payment is usually a part of the profit of the company. A company’s dividend is mostly determined by its board of directors and it requires the shareholders’ approval. MannKind Corporation (NASDAQ:MNKD)for the trailing twelve months paying dividend with the payout ratio of 0.00% to its shareholders. Currently it is offering a dividend yield of 0.00% and a 5 year dividend growth rate of 0.00%. Over the last year Company’s shares have been trading in the range of $0.67 and $6.96. The stock is above its 52-week low with 374.33% and is in the wake of its 52-week high with -54.60%.
Performance & Technicalities
In the latest week MannKind Corporation (NASDAQ:MNKD) stock volatility was recorded 6.18% which for the previous full month was noted 8.78%. Meanwhile the stock weekly performance was subdued at -0.32%, which was down for the month at -6.23%. Likewise, the upbeat performance for the last quarter was 91.52% and for the full year it was 18.82%. Moreover the Company’s Year To Date performance was -0.74%. Now a days one of the fundamental indicator used in the technical analysis is called Stochastic %D”, Stochastic indicator was created by George Lane. The stochastic is a momentum indicator comparing the closing price of a security to the range of its prices over a fix period of time. The gauge is based on the assumption that if price surges, the closing price tends towards the values that belong to the upper part of the area of price movements in the preceding period. On the other hand if price drops, the contrary is right. For MannKind Corporation (NASDAQ:MNKD), Stochastic %D value stayed at 18.58% for the last 9 days. Considering more the value stands at 25.40% and 25.40% for 14 and 20 days, in that order.
-------------------------------------------
November 16th 2017 - Staff Writer
Rumor - Synergy Pharmaceuticals (SGYP) rejected Merck (MRK) latest offer as too low!
------------------------------------------
Finance Registar - November 16th 2017 CANNABIS BREAKOUT SPOTLIGHT ON OWC PHARMACEUTICAL RESEARCH CORP (OTCMKTS:OWCP)
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) broke out this week on a gigantic move. The stock is in a red-hot market space of late, and today’s breakout took shares above the 50-day simple moving average in a big way. The single-day move took it up 30% in a straight line on a jump in volume. For a little context, keep in mind that this thing is coming off a pullback from the $3/share level after trading under $0.02/share last Fall. So, it’s been a roller coaster ride over the past year. Wednesday’s move was one of the strongest we’ve seen out of shares of OWCP in the last six months. The move comes off a higher base of support around the $0.30 level, suggesting the stock is now possibly in the midst of a new and burgeoning upward trend.
Catalyzing Wednesday’s move, we saw 8K out of the company advertising changes to the Board of Directors for the added an experienced CPA. That’s always a good sign because it suggests the company’s finances are in order. The company also noted that it was granted a patent in Australia for proprietary cream for the treatment of skin disorders.
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) casts itself as a company that engages in the research and development of Cannabis-based medical products. The company provides medical products for the treatment of various medical conditions and/or diseases, such as multiple myeloma, psoriasis, PTSD, and migraines; and delivery systems. It also provides consulting services to companies and governmental agencies related to international medical cannabis protocols and regulations.
OWCP through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals, treatments and unique delivery systems for the effective delivery and dosage of medical cannabis.
All OWC research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators.
OWCP’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.
The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. The company was formerly known as Dynamic Applications Corp. OWC Pharmaceutical Research Corp. was founded in 2008 and is based in Petach Tikva, Israel.
As noted above, shares of OWCP broke higher today in a feverish move that rocketed the stock up as much as 30%. The Cannabis patch has been on fire once again over the past month, and the company added fuel to the fire by beefing up its fiduciary team on the board as well as announcing some new global market IP value.
Ms. Hannah Feuer, Age 62, Director and Chairman of the Audit Committee: Ms. Feuer is a CPA and Senior CFO with more than 20 years of experience in capital markets and management in financial institutions. During Ms. Feuer’s professional career, she has developed significant expertise working with boards of directors of both financial institutions and major companies and has extensive knowledge of public offerings and underwriting, as well as raising and managing private equity funds.
Also according to the 8K, “on November 8, 2018, the Registrant was granted a Certificate of Patent, #2015101908 (the “Innovation Patent”) from the Commissioner of Patents, Commonwealth of Australia, for the Registrant’s proprietary cream for the treatment of skin disorders. The Registrant’s skin cream has been proven, pre-clinically, to lower various inflammatory markers by up to 70% and to inhibit Keratocytes proliferation, a manifestation of various skin disorders, especially Psoriasis.”
Currently trading at a market capitalization of $66.4M, OWCP has a bankroll ($1.4M) of cash on the books, which compares with virtually no total current liabilities. OWCP is pulling in trailing 12-month revenues of $50K. However, the company is seeing a recent flattening of growth on the top-line on a sequential quarterly basis. You can bet we will update this one again as new information comes into view.
________________________
